← SynDRA
AVAPRITINIB
SynDRA canonical compound SYN0039315 — structure-anchored drug synonym record
| Clinical phase | Launched |
|---|
| Approval status | Approved · Rx |
|---|
| Primary target(s) | KIT |
|---|
| Mechanism of action | KIT inhibitor |
|---|
All known targets
Mechanisms of action (all sources)
- KIT INHIBITOR
- Stem cell growth factor receptor inhibitor
- PDGFRA INHIBITOR
- Platelet-derived growth factor receptor alpha inhibitor
Bioactivity evidence (ChEMBL activities table — not curator-asserted)
Screening evidence (raw PubChem HTS — uncurated, known false-positive rate)
Drug classes
- Tyrosine Kinase Inhibitors
- Kinase Inhibitor
- P-Glycoprotein Inhibitors
- Cytochrome P450 2C9 Inhibitors
- Breast Cancer Resistance Protein Inhibitors
- Multidrug and Toxin Extrusion Transporter 1 Inhibitors
- Bile Salt Export Pump Inhibitors
- Multidrug and Toxin Extrusion Transporter 2 K Inhibitors
ATC classes
- L01E · PROTEIN KINASE INHIBITORS
Cross-references
Synonyms
- AYVAKIT
- Ayvakit
- BLU-285
- ayvakit
- 70C366
- C-366
- X-720776
- X720776
- Ayvakyt
- UNII-513P80B4YJ
- 513P80B4YJ
- Avapritinib [INN]
- BLU-285 (Avapritinib)
- SCHEMBL16652297
- EX-A1366
- BCP20175
- CS-7577
- ACN-051245
- HY-101561
- BLU 285
- avapritinibum
- RefChem:56916
- DTXCID501513502
- CS3007
- PDGFR alpha/KIT Mutant-specific Inhibitor BLU-285
- MFCD31544325
- BLU285
- Avapritinib (BLU-285)
- 9JI
- Ayvakit (TN)
- Ayvakyt (TN)
- Avapritinib (Standard)
- AVAPRITINIB [MI]
- Avapritinib (USAN/INN)
- AVAPRITINIB [USAN]
- AVAPRITINIB [WHO-DD]
- orb1302083
- GTPL10368
Reported adverse events
- Abdominal pain
- Alopecia
- Arthralgia
- Constipation
- Dizziness
- Epistaxis
- Fatigue
- Flushing
- Headache
- Insomnia
- Nausea
- Pleural effusion
Look up AVAPRITINIB in the interactive SynDRA portal →